Novo nordisk announces presentation of data from key semaglutide clinical trials in diabetes, obesity and chronic kidney disease at the 84th scientific sessions of the american diabetes association

BagsvÆrd, denmark, 18 june 2024 – novo nordisk today announced the presentation of 34 abstracts highlighting the breadth of its portfolio at the upcoming 84th scientific sessions of the american diabetes association (ada). the conference will be held in-person and virtually from 21–24 june 2024 in orlando, us.
NVO Ratings Summary
NVO Quant Ranking